256 related articles for article (PubMed ID: 10052905)
1. Moxifloxacin: a comparison with other antimicrobial agents of in-vitro activity against Streptococcus pneumoniae.
Reinert RR; Schlaeger JJ; Lütticken R
J Antimicrob Chemother; 1998 Dec; 42(6):803-6. PubMed ID: 10052905
[TBL] [Abstract][Full Text] [Related]
2. A comparative study of the in-vitro activity of levofloxacin against Streptococcus pneumoniae.
Reinert RR; Lütticken R; Lemperle M; Bryskier A
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():5-8. PubMed ID: 10404330
[TBL] [Abstract][Full Text] [Related]
3. Antimicrobial activity of moxifloxacin, gatifloxacin and six fluoroquinolones against Streptococcus pneumoniae.
Saravolatz L; Manzor O; Check C; Pawlak J; Belian B
J Antimicrob Chemother; 2001 Jun; 47(6):875-7. PubMed ID: 11389122
[TBL] [Abstract][Full Text] [Related]
4. In vitro activity of gemifloxacin against Streptococcus pneumoniae isolates in Germany.
Lemmen S; Al-Lahham A; Lütticken R; Reinert RR
Chemotherapy; 2001; 47(2):104-9. PubMed ID: 11173811
[TBL] [Abstract][Full Text] [Related]
5. Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.
Buxbaum A; Straschil U; Moser C; Graninger W; Georgopoulos A
J Antimicrob Chemother; 1999 May; 43 Suppl B():13-8. PubMed ID: 10382870
[TBL] [Abstract][Full Text] [Related]
6. Activity of moxifloxacin and twelve other antimicrobial agents against 216 clinical isolates of Streptococcus pneumoniae.
Esposito S; Noviello S; Ianniello F
Chemotherapy; 2001; 47(2):90-6. PubMed ID: 11173809
[TBL] [Abstract][Full Text] [Related]
7. In-vitro bacteriostatic activity of levofloxacin and three other fluoroquinolones against penicillin-susceptible and penicillin-resistant Streptococcus pneumoniae.
Frémaux A; Sissia G; Geslin P
J Antimicrob Chemother; 1999 Jun; 43 Suppl C():9-14. PubMed ID: 10404331
[TBL] [Abstract][Full Text] [Related]
8. Activity of moxifloxacin and other quinolones against pneumococci resistant to first-line agents, or with high-level ciprofloxacin resistance.
Johnson AP; Warner M; Livermore DM
Int J Antimicrob Agents; 2001 May; 17(5):377-81. PubMed ID: 11337224
[TBL] [Abstract][Full Text] [Related]
9. Moxifloxacin sensitivity of respiratory pathogens in the United Kingdom.
Dorai-John T; Thomson CJ; Amyes SG
J Chemother; 2002 Feb; 14(1):19-24. PubMed ID: 11892894
[TBL] [Abstract][Full Text] [Related]
10. Activity of oral agents against pediatric isolates of Streptococcus pneumoniae.
Black J; Moland ES; Chartrand SA; Thomson KS
Diagn Microbiol Infect Dis; 2001 Mar; 39(3):195-7. PubMed ID: 11337189
[TBL] [Abstract][Full Text] [Related]
11. Bactericidal activity of moxifloxacin compared to grepafloxacin and clarithromycin against Streptococcus pneumoniae and Streptococcus pyogenes investigated using an in vitro pharmacodynamic model.
Esposito S; Noviello S; Ianniello F
J Chemother; 2000 Dec; 12(6):475-81. PubMed ID: 11154028
[TBL] [Abstract][Full Text] [Related]
12. Comparative activity of trovafloxacin and Bay 12-8039 against 452 clinical isolates of Streptococcus pneumoniae.
Weiss K; Laverdiere M; Restieri C
J Antimicrob Chemother; 1998 Oct; 42(4):523-5. PubMed ID: 9818753
[TBL] [Abstract][Full Text] [Related]
13. Comparative in vitro activity of penicillin G, levofloxacin, moxifloxacin, telithromycin, pristinamycin, quinupristin-dalfopristin and linezolid against ofloxacin-intermediate and -resistant Streptococcus pneumoniae.
Frédénucci I; Chomarat M; Bercion R; Carricajo A; Celard M; Croizé J; Delubac F; Fèvre D; Fuhrmann C; Helfre M; Letouzey MN; Lelièvre H; Mandjee A; Marthelet P; Meley R; Perrier-Gros-Claude JD; Ros A; Roure C; Smati S; Thierry J; Tous J
Clin Microbiol Infect; 2002 Oct; 8(10):680-3. PubMed ID: 12390289
[TBL] [Abstract][Full Text] [Related]
14. Concentration-dependent killing of antibiotic-resistant pneumococci by the methoxyquinolone moxifloxacin.
Klugman KP; Capper T
J Antimicrob Chemother; 1997 Dec; 40(6):797-802. PubMed ID: 9462430
[TBL] [Abstract][Full Text] [Related]
15. Pharmacodynamics of moxifloxacin, levofloxacin and sparfloxacin against Streptococcus pneumoniae.
Lister PD; Sanders CC
J Antimicrob Chemother; 2001 Jun; 47(6):811-8. PubMed ID: 11389113
[TBL] [Abstract][Full Text] [Related]
16. Comparative in-vitro activity of moxifloxacin, penicillin, ceftriaxone and ciprofloxacin against pneumococci isolated from meningitis.
Tarasi A; Capone A; Tarasi D; Cassone M; Bianco G; Venditti M
J Antimicrob Chemother; 1999 Jun; 43(6):833-5. PubMed ID: 10404324
[TBL] [Abstract][Full Text] [Related]
17. Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.
Jones ME; Staples AM; Critchley I; Thornsberry C; Heinze P; Engler HD; Sahm DF
Diagn Microbiol Infect Dis; 2000 Jul; 37(3):203-11. PubMed ID: 10904194
[TBL] [Abstract][Full Text] [Related]
18. Comparative bactericidal activities of ciprofloxacin, clinafloxacin, grepafloxacin, levofloxacin, moxifloxacin, and trovafloxacin against Streptococcus pneumoniae in a dynamic in vitro model.
Klepser ME; Ernst EJ; Petzold CR; Rhomberg P; Doern GV
Antimicrob Agents Chemother; 2001 Mar; 45(3):673-8. PubMed ID: 11181341
[TBL] [Abstract][Full Text] [Related]
19. [Pneumococcus and quinolone resistance].
Bello S; Torres A
Arch Bronconeumol; 2003 Mar; 39(3):97-100. PubMed ID: 12622966
[No Abstract] [Full Text] [Related]
20. Antipneumococcal activity of BAY 12-8039, a new quinolone, compared with activities of three other quinolones and four oral beta-lactams.
Visalli MA; Jacobs MR; Appelbaum PC
Antimicrob Agents Chemother; 1997 Dec; 41(12):2786-9. PubMed ID: 9420061
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
